Flavie Moreau
About
Flavie Moreau is a scholar working on Rheumatology, Infectious Diseases and Epidemiology.
According to data from OpenAlex, Flavie Moreau has authored 23 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 8 papers in Infectious Diseases and 7 papers in Epidemiology. Recurrent topics in Flavie Moreau's work include Osteoarthritis Treatment and Mechanisms (10 papers), Tuberculosis Research and Epidemiology (7 papers) and Mycobacterium research and diagnosis (6 papers). Flavie Moreau is often cited by papers focused on Osteoarthritis Treatment and Mechanisms (10 papers), Tuberculosis Research and Epidemiology (7 papers) and Mycobacterium research and diagnosis (6 papers). Flavie Moreau collaborates with scholars based in Germany, United States and France. Flavie Moreau's co-authors include Wladimir Malaga, Catherine Astarie‐Dequeker, Christophe Guilhot, Charlotte Passemar, C. Ladel, Carlos Martı́n, Hans Guehring, Roland Brosch, Alexandre Pawlik and F. Eckstein and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Antimicrobial Agents and Chemotherapy.
In The Last Decade
Flavie Moreau
22 papers receiving 482 citations
Peers
Flavie Moreau
O Rojas-Espinosa Mexico
Ricardo Alberto Moliterno Brazil
Kenta Matsuda Japan
Inès Ambite Sweden
Stephen Perusini Canada
Yoann Crabol France
Kanako Yoshida Japan
Melanie Schott Germany
Patricia Souza Brazil
David H Felix United Kingdom
Citations per year, relative to Flavie Moreau Flavie Moreau (= 1×)
peers
O Rojas-Espinosa
Countries citing papers authored by Flavie Moreau
Since
Specialization
Citations
This map shows the geographic impact of Flavie Moreau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Flavie Moreau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Flavie Moreau more than expected).
Fields of papers citing papers by Flavie Moreau
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Flavie Moreau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Flavie Moreau. The network helps show where Flavie Moreau may publish in the future.
Co-authorship network of co-authors of Flavie Moreau
This figure shows the co-authorship network connecting the top 25 collaborators of Flavie Moreau. A scholar is included among the top collaborators of Flavie Moreau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Flavie Moreau. Flavie Moreau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Witte, T, et al.. (2025). Enpatoran, a first-in-class, selective, orally administered toll-like receptor 7/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study. Lupus Science & Medicine. 12(2). e001705–e001705.
2.
Pearson, David R., Eric F. Morand, Joerg Wenzel, et al.. (2025). RANDOMIZED, PLACEBO-CONTROLLED PHASE II STUDY OF ENPATORAN, A SMALL MOLECULE TOLL-LIKE RECEPTOR 7/8 INHIBITOR, IN CUTANEOUS LUPUS ERYTHEMATOSUS: RESULTS FROM COHORT A. The Journal of Rheumatology. 52(Suppl 1). 11.1–11.
3.
Bihlet, Asger Reinstrup, Kosalaram Goteti, Jesper Sonne, et al.. (2024). Safety, Tolerability, and Pharmacodynamics of the ADAMTS ‐5 Nanobody M6495 : Two Phase 1, Single‐Center , Double‐Blind , Randomized, Placebo‐Controlled Studies in Healthy Subjects and Patients With Osteoarthritis. ACR Open Rheumatology. 6(4). 205–213.
4.
Malaga, Wladimir, Delphine Payros, Wafa Frigui, et al.. (2023). Natural mutations in the sensor kinase of the PhoPR two-component regulatory system modulate virulence of ancestor-like tuberculosis bacilli. PLoS Pathogens. 19(7). e1011437–e1011437.
5.
McKinnon, John E., Cláudia Murta de Oliveira, Dongzi Yu, et al.. (2023). Enpatoran in COVID ‐19 pneumonia: Safety and efficacy results from a phase II randomized trial. Clinical and Translational Science. 16(12). 2640–2653.
6.
Morand, Eric F., Victoria P. Werth, Andrew T. Bender, et al.. (2022). 1501 Enpatoran: preclinical evidence supporting glucocorticoid dose reduction and Phase II study design in patients with SLE and/or CLE (WILLOW). SHILAP Revista de lepidopterología. A93–A94.
7.
Payros, Delphine, Henar Alonso, Wladimir Malaga, et al.. (2021). Rv0180c contributes to Mycobacterium tuberculosis cell shape and to infectivity in mice and macrophages. PLoS Pathogens. 17(11). e1010020–e1010020.
8.
Allen, Aideen C., Wladimir Malaga, Cyril Gaudin, et al.. (2021). Parallel in vivo experimental evolution reveals that increased stress resistance was key for the emergence of persistent tuberculosis bacilli. Nature Microbiology. 6(8). 1082–1093.
9.
Eckstein, F., Marc C. Hochberg, Hans Guehring, et al.. (2021). Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. Annals of the Rheumatic Diseases. 80(8). 1062–1069.
10.
Guehring, Hans, Flavie Moreau, C. Ladel, et al.. (2021). The effects of sprifermin on symptoms and structure in a subgroup at risk of progression in the FORWARD knee osteoarthritis trial. Seminars in Arthritis and Rheumatism. 51(2). 450–456.
11.
Eckstein, F., Marc C. Hochberg, Hans Guehring, et al.. (2020). Long-term efficacy and safety of intra-articular sprifermin in patients with knee osteoarthritis: results from the 5-year forward study. Osteoarthritis and Cartilage. 28. S77–S78.
12.
Brett, Alan, M.A. Bowes, Philip G. Conaghan, et al.. (2020). Automated MRI assessment confirms cartilage thickness modification in patients with knee osteoarthritis: post-hoc analysis from a phase II sprifermin study. Osteoarthritis and Cartilage. 28(11). 1432–1436.
13.
Bay‐Jensen, Anne‐Christine, Angela A. Manginelli, Flavie Moreau, et al.. (2020). Assessment of cartilage markers in synovial fluid from the forward study provide insight to the biphasic effect of sprifermin. Osteoarthritis and Cartilage. 28. S496–S497.
14.
Gühring, Hans, Anne‐Christine Bay‐Jensen, Flavie Moreau, et al.. (2020). FRI0404 SEPERATION OF HIGH AND LOW RESPONSE GROUPS IN OSTEOARTHRITIS USING SERUM CARTILAGE DEGRADATION AND FORMATION MARKERS – A 3 YEAR FOLLOW-UP ON THE FORWARD STUDY TESTING THE EFFICACY OF SPRIFERMIN. Annals of the Rheumatic Diseases. 79. 800–801.
15.
Brett, Alan, M.A. Bowes, Philip G. Conaghan, et al.. (2019). SAT0647 MRI DATA FROM THE SPRIFERMIN PHASE II FORWARD STUDY: CONFIRMATION OF MANUAL CARTILAGE SEGMENTATION FINDINGS BY AUTOMATED SEGMENTATION. Annals of the Rheumatic Diseases. 78. 1421–1423.
16.
Gühring, Hans, Flavie Moreau, C. Ladel, et al.. (2019). OP0010 CARTILAGE THICKNESS MODIFICATION WITH SPRIFERMIN IN KNEE OSTEOARTHRITIS PATIENTS TRANSLATES INTO SYMPTOMATIC IMPROVEMENT OVER PLACEBO IN PATIENTS AT RISK OF FURTHER STRUCTURAL AND SYMPTOMATIC PROGRESSION: POST-HOC ANALYSIS OF THE PHASE II FORWARD TRIAL. Annals of the Rheumatic Diseases. 78. 70–71.
17.
Strotmann, Rainer, Asger Reinstrup Bihlet, Jesper Sonne, et al.. (2018). Study design of a phase I, placebo-controlled, First-in-human trial to assess safety and tolerability, immunogenicity, and pharmacokinetics and pharmacodynamics of single ascending doses of the anti-ADAMTS-5 Nanobody®, M6495, in healthy male subjects. Osteoarthritis and Cartilage. 26. S276–S277.
18.
Trefz, Friedrich K., Ania C. Muntau, Florian B. Lagler, et al.. (2015). The Kuvan® Adult Maternal Paediatric European Registry (KAMPER) Multinational Observational Study: Baseline and 1-Year Data in Phenylketonuria Patients Responsive to Sapropterin. JIMD Reports. 23. 35–43.
19.
Gonzalo‐Asensio, Jesús, Wladimir Malaga, Alexandre Pawlik, et al.. (2014). Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator. Proceedings of the National Academy of Sciences. 111(31). 11491–11496.
20.
Passemar, Charlotte, Ainhoa Arbués, Wladimir Malaga, et al.. (2013). Multiple deletions in the polyketide synthase gene repertoire ofMycobacterium tuberculosisreveal functional overlap of cell envelope lipids in host-pathogen interactions. Cellular Microbiology. 16(2). 195–213.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by O Rojas-Espinosa Breakdown of academic impact, for papers by Ricardo Alberto Moliterno Breakdown of academic impact, for papers by Kenta Matsuda Breakdown of academic impact, for papers by Inès Ambite Breakdown of academic impact, for papers by Stephen Perusini Breakdown of academic impact, for papers by Yoann Crabol Breakdown of academic impact, for papers by Kanako Yoshida Breakdown of academic impact, for papers by Melanie Schott Breakdown of academic impact, for papers by Patricia Souza Breakdown of academic impact, for papers by David H Felix